×
About 2,628 results

ALLMedicine™ Allergic Conjunctivitis Center

Research & Reviews  440 results

Factors associated with severity of atopic dermatitis - a Finnish cross-sectional study.
https://doi.org/10.1111/jdv.18378
Journal of the European Academy of Dermatology and Venere... Salava A, Salo V et. al.

Jun 30th, 2022 - Severity associated factors in atopic dermatitis (AD) have focused on early onset, concomitant atopic diseases, markers of Th2-shifted inflammation and filaggrin mutations. To investigate factors associated with severe AD in Finnish patients. We c...

Clinical Characteristics, Health Care Resource Utilization, and Prescription Patterns o...
https://doi.org/10.1159/000524740
International Archives of Allergy and Immunology; Yoshisue H, Ito C et. al.

May 23rd, 2022 - Allergic rhinitis (AR) is associated with a substantial health care burden. In Japan, clinical patient profiles in real-life settings and evidence on economic burden of AR are limited. We studied clinical characteristics of patients with AR in Jap...

In brief: OTC alcaftadine (Lastacaft Once Daily Relief) for allergic conjunctivitis.
https://www.ncbi.nlm.nih.gov/pubmed/35536123
The Medical Letter on Drugs and Therapeutics;

May 11th, 2022 - In brief: OTC alcaftadine (Lastacaft Once Daily Relief) for allergic conjunctivitis.|2022||adverse effects,therapeutic use,diagnosis,drug therapy,therapeutic use,therapeutic use,

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05234554

May 10th, 2022 - The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seaso...

The Protective Effects of KAT5 Inhibition on Ocular Inflammation by Mediating the PI3K/...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078075
Investigative Ophthalmology & Visual Science; Luo F, Tao Y et. al.

May 4th, 2022 - We aimed to explore the effect of lysine acetyltransferase KAT5 on allergic conjunctivitis (AC). The effect of KAT5 on inflammatory response during AC progression was analyzed in the experimental allergic conjunctivitis (EAC) mouse model. The clin...

see more →

Drugs  441 results see all →

Clinicaltrials.gov  119 results

The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05234554

May 10th, 2022 - The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seaso...

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05265910

May 3rd, 2022 - This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated c...

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
https://clinicaltrials.gov/ct2/show/NCT04622345

Apr 27th, 2022 - The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT04708821

Apr 13th, 2022 - This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to compare patient-reported and clinical outcomes with DEXTENZA versus topical steroid or antihistamine treatment in patients with allergic conjun...

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
https://clinicaltrials.gov/ct2/show/NCT05314621

Apr 6th, 2022 - At Visit 1, subjects will sign the informed consent and an allergic skin test will be performed, if required. Each qualifying subject will undergo a bilateral conjunctival allergen challenge (Ora-CAC®) titration using an allergen they had a positi...

see more →

News  49 results

Unilateral eye irritation
https://www.mdedge.com/familymedicine/article/254196/unilateral-eye-irritation
MDedge Family Medicine;

Apr 28th, 2022 - Physical examination revealed an irregularly shaped conjunctival cyst on the lateral (temporal) field of the right eye. (This diagnosis is usually made based on the clinical examination alone.

First Drug-Eluting Contact Lens Wins FDA Nod
https://www.medpagetoday.com/allergyimmunology/allergy/97480

Mar 3rd, 2022 - A drug-eluting contact lens containing an antihistamine for people with allergic eye itch won approval from the FDA, Johnson & Johnson Vision Care announced. The daily disposable etafilcon A drug-eluting contact lens with ketotifen (Acuvue Theravi...

FDA Approvals, Highlights, and Summaries: Ophthalmology 
https://www.medscape.com/viewarticle/967614

Feb 17th, 2022 - Tyrvaya (varenicline intranasal) Varenicline intranasal is indicated for treatment of signs and symptoms of dry eye disease. Varenicline binds to highly selective heteromeric subtype(s) of the nicotinic acetylcholine receptor, which produces agoni...

FDA Approvals, Highlights, and Summaries: Ophthalmology 
https://reference.medscape.com/viewarticle/967614

Feb 17th, 2022 - Tyrvaya (varenicline intranasal) Varenicline intranasal is indicated for treatment of signs and symptoms of dry eye disease. Varenicline binds to highly selective heteromeric subtype(s) of the nicotinic acetylcholine receptor, which produces agoni...

One in 15 Patients Who Start Dupilumab May Develop Conjunctivitis, Large Analysis Finds
https://www.medscape.com/viewarticle/953387

Jun 18th, 2021 - One in 15 patients who start dupilumab treatment may develop conjunctivitis during the first 6 months, most of which is manageable with ophthalmic treatments, results from large study of U.S. claims data showed. "About 4 years after dupilumab's ap...

see more →

Patient Education  2 results see all →